Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Buying Allergan's US dermatology portfolio will expand the Spanish group's platform in the world's largest dermatology market.
You may also be interested in...
Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.
CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.